Axon Enterprise (NASDAQ:AXON) Price Target Raised to $500.00

Axon Enterprise (NASDAQ:AXON) had its price objective raised by JMP Securities from $430.00 to $500.00 in a research note released on Thursday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

AXON has been the topic of several other research reports. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Craig Hallum boosted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Northland Securities boosted their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Barclays boosted their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Robert W. Baird boosted their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $388.23.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $425.84 on Thursday. Axon Enterprise has a 1-year low of $209.02 and a 1-year high of $455.17. The firm’s 50 day simple moving average is $402.34 and its two-hundred day simple moving average is $340.57. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market capitalization of $32.18 billion, a P/E ratio of 112.36, a P/E/G ratio of 10.78 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the previous year, the firm earned $0.80 earnings per share. The company’s quarterly revenue was up 34.5% compared to the same quarter last year. Research analysts expect that Axon Enterprise will post 1.79 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 25,811 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the transaction, the president now owns 228,166 shares in the company, valued at $82,103,253.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the transaction, the president now owns 228,166 shares of the company’s stock, valued at $82,103,253.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jeffrey C. Kunins sold 8,182 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $364.86, for a total transaction of $2,985,284.52. Following the completion of the transaction, the insider now directly owns 176,228 shares in the company, valued at $64,298,548.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock worth $137,000,162 over the last quarter. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock worth $2,547,878,000 after acquiring an additional 212,401 shares in the last quarter. Motley Fool Asset Management LLC grew its holdings in Axon Enterprise by 238.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after acquiring an additional 346,838 shares in the last quarter. 1832 Asset Management L.P. grew its holdings in Axon Enterprise by 44.0% during the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after acquiring an additional 114,800 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Axon Enterprise by 13.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after acquiring an additional 45,049 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in Axon Enterprise by 1.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock worth $79,571,000 after acquiring an additional 4,365 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.